DK3770162T3 - Dihydrochromenderivater - Google Patents

Dihydrochromenderivater Download PDF

Info

Publication number
DK3770162T3
DK3770162T3 DK19770755.7T DK19770755T DK3770162T3 DK 3770162 T3 DK3770162 T3 DK 3770162T3 DK 19770755 T DK19770755 T DK 19770755T DK 3770162 T3 DK3770162 T3 DK 3770162T3
Authority
DK
Denmark
Prior art keywords
dihydrochrome
derivatives
dihydrochrome derivatives
Prior art date
Application number
DK19770755.7T
Other languages
Danish (da)
English (en)
Inventor
Hitoshi Ban
Seiji Kamioka
Yusuke Sawayama
Miki Hashizume
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Application granted granted Critical
Publication of DK3770162T3 publication Critical patent/DK3770162T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK19770755.7T 2018-03-20 2019-03-19 Dihydrochromenderivater DK3770162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Publications (1)

Publication Number Publication Date
DK3770162T3 true DK3770162T3 (da) 2023-04-24

Family

ID=67986459

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19770755.7T DK3770162T3 (da) 2018-03-20 2019-03-19 Dihydrochromenderivater

Country Status (21)

Country Link
US (3) US10807993B2 (https=)
EP (1) EP3770162B1 (https=)
JP (4) JP6733072B2 (https=)
KR (1) KR102799186B1 (https=)
CN (1) CN111886237B (https=)
AU (1) AU2019239481B2 (https=)
CA (1) CA3092255A1 (https=)
CY (1) CY1126034T1 (https=)
DK (1) DK3770162T3 (https=)
EA (1) EA202092206A1 (https=)
ES (1) ES2941771T3 (https=)
FI (1) FI3770162T3 (https=)
HU (1) HUE062256T2 (https=)
MX (1) MX2020009763A (https=)
MY (1) MY202583A (https=)
PH (1) PH12020551497A1 (https=)
PL (1) PL3770162T3 (https=)
PT (1) PT3770162T (https=)
SG (1) SG11202007979UA (https=)
TW (1) TWI899051B (https=)
WO (1) WO2019181939A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3770162T3 (pl) * 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2025100519A1 (ja) * 2023-11-09 2025-05-15 住友ファーマ株式会社 ジヒドロクロメン誘導体を含むがんの治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20080255149A1 (en) * 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
RU2018101897A (ru) * 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) * 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
TW201821105A (zh) * 2016-10-20 2018-06-16 美商弗瑪治療公司 使用hdac11抑制劑之方法
PL3770162T3 (pl) 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
JP2020019752A (ja) 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Also Published As

Publication number Publication date
KR102799186B1 (ko) 2025-04-23
CN111886237A (zh) 2020-11-03
US20230219970A1 (en) 2023-07-13
JP6733072B2 (ja) 2020-07-29
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP2024123117A (ja) 2024-09-10
FI3770162T3 (fi) 2023-06-02
AU2019239481A1 (en) 2020-09-10
KR20200135401A (ko) 2020-12-02
CA3092255A1 (en) 2019-09-26
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
BR112020017481A8 (pt) 2022-12-06
CY1126034T1 (el) 2023-11-15
JPWO2019181939A1 (ja) 2020-06-18
SG11202007979UA (en) 2020-09-29
US10807993B2 (en) 2020-10-20
EP3770162A4 (en) 2021-12-01
US11639357B2 (en) 2023-05-02
EP3770162A1 (en) 2021-01-27
PL3770162T3 (pl) 2023-06-05
HUE062256T2 (hu) 2023-10-28
MY202583A (en) 2024-05-09
US12398149B2 (en) 2025-08-26
CN111886237B (zh) 2025-02-07
JP7508620B2 (ja) 2024-07-01
ES2941771T3 (es) 2023-05-25
EA202092206A1 (ru) 2020-12-15
JP2023075288A (ja) 2023-05-30
NZ767234A (en) 2025-06-27
JP2020180140A (ja) 2020-11-05
AU2019239481B2 (en) 2022-11-24
BR112020017481A2 (pt) 2020-12-22
PT3770162T (pt) 2023-03-23
JP7247144B2 (ja) 2023-03-28
TWI899051B (zh) 2025-10-01
PH12020551497A1 (en) 2021-09-01
WO2019181939A1 (ja) 2019-09-26
TW201941774A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
EP3890716A4 (en) COMBINATION THERAPIES
EP3555124C0 (en) TCR NYESO
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
EP3781060A4 (en) CRYOPROBE
DK3768669T3 (da) Piperazinazaspiroderivater
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3784463A4 (en) Fluorosulfones
EP3810860C0 (en) COUPLER
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3792200A4 (en) TANK TANK
EP3745904C0 (de) Stockgriff
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3796975T3 (da) Sulfonylaminobenzamidderivater
EP3721129A4 (en) CRYOSPHERE
DK3645513T3 (da) Benzazepinderivater
DK3894410T3 (da) Substituerede xanthinderivater
DK3770162T3 (da) Dihydrochromenderivater
EP3844177A4 (en) COMBINATION THERAPIES
DK3587968T3 (da) Fluidsystem
EP3595647A4 (en) ARYL-PIPERIDINE DERIVATIVES
EP3773733A4 (en) METALLO-LIOTHYRONINE
DK3752258T3 (da) Trampolin